Imaging Edge: Why You Should Consider MRI Biomarkers for Parkinson’s Disease Clinical Trials

Parkinson’s clinical research is evolving, and imaging biomarkers are playing a growing role in improving trial precision and regulatory confidence. This focused guide explores three MRI techniques that are gaining traction in the field: structural MRI, neuromelanin-sensitive MRI, and free water imaging.

What you’ll learn in this FREE EBOOK:

Which MRI biomarkers are showing the strongest translational potential in PD
How imaging can improve patient stratification and endpoint sensitivity
Why regulators are increasingly open to imaging-based efficacy measures
Practical considerations for scaling imaging across multi-site trials
How QMENTA helps sponsors implement imaging biomarkers at scale.